EUCTR2017-000594-37-GB进行中（未招募）1 期
A Phase 2, Open-label, Single arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) - Phase 2 Study of Pembrolizumab in Participants With R/M cSCC
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.R/M disease cohort only-All participants must have cSCC that is either metastatic, defined as disseminated disease, and/or unresectable disease that is not curable by surgery or radiation.
- •2.Participants must have histologically confirmed cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted)
- •3. LA disease cohort only – Participants must be ineligible for surgical resection.
- •4. LA disease cohort only – Participants who received prior radiation therapy(RT) to index site or must be deemed to be not eligible for RT.
- •5. LA disease cohort only – Participants who received prior systemic therapy for curative intent are eligible regardless of regimen.
- •6.R/M disease cohort only–Participants must have metastatic disease, defined as disseminated disease distant to the initial/primary site of diagnosis, and/or must have locally recurrent disease that has been previously treated (with either surgery or radiotherapy) and is not curable by either surgery or radiotherapy.
- •7.Participants must have measurable disease based on RECIST 1.1 as assessed by the central imaging vendor. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
- •8.Participants must have e an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days prior to the start of treatment
- •9.Participants must have adequate organ function as defined in the protocol.Specimens must be collected within 10 days prior to the start of treatment
- •10.Participants must have a tissue sample adequate for PD-L1 testing as determined by central laboratory testing prior to trial allocation. This tissue sample may be obtained from either a newly obtained core or excisional biopsy, or a prior archival tissue specimen
- •11.Participants must have a life expectancy of greater than 3 months
- •12. Be at least 18 years of age on the day of signing the informed consent.
- •13.Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of trial medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •14.A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies: a.) Not a woman of childbearing potential (WOCBP) OR b.) A WOCBP who agrees to use an adequate method of contraception as detailed in the protocol, during the treatment period and for at least 120 days after the last dose of study treatment
- •15.The participant (or legally acceptable representative if applicable) must be willing and able to provide written informed consent for the trial. The participant may also provide consent for Future Biomedical Research. However the participant may participate in the main trial without participating in Future Biomedical Research
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •1.Participant has cSCC that can be cured with surgical resection, radiotherapy, or with a combination of surgery and radiotherapy.
- •2.Participant has any other histologic type of skin cancer other than invasive squamous cell carcinoma as the primary disease under study, eg, basal cell carcinoma that has not been definitively treated with surgery or radiation, Bowen’s disease, MCC, melanoma
- •3.Participants with any prior allogeneic solid organ or bone marrow transplantations are excluded
- •4.Participant has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor (eg, CTLA-4, OX-40, CD137)
- •5.Participant has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
- •6.Participant has received prior radiotherapy within 2 weeks of start of trial treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-central nervous system (CNS) disease
- •7.Participant has received a live vaccine within 30 days prior to the first dose of trial drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killedvirus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live- attenuated vaccines and are not allowed
- •8.Participant is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment
- •9.Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial drug
- •10 Participant has a diagnosis and/or has been treated for additional malignancy within the past 5 years prior to allocation
- •11.Participant has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for at least 7 days prior to first dose of trial treatment
- •12. Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients
- •13.Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (eg, with use of disease-modifying agents, anticoagulants, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- •14.Participant has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
- •15.Participant has an active infection requiring systemic therapy
- •16.Participant has a known history of human immunodeficiency virus (HIV) infection
- •17.Participant has a known histor
研究者
相似试验
进行中（未招募）
1 期
A Phase II, Open-label, Single arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell CarcinomaRecurrent or Metastatic (R/M) Cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC.MedDRA version: 21.1Level: PTClassification code 10041834Term: Squamous cell carcinoma of skinSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000594-37-DEMerck Sharp & Dohme LLC150
撤回
2 期
A Phase 2, Open-label, Single-arm Study to Evaluate the Tolerability, Safety, and Pharmacodynamic Effects of KER-012 in Participants with Chronic Heart Failure.Cardiovascular - Other cardiovascular diseasesChronic Heart FailureACTRN12623001290684Keros Therapeutics, Inc.12
进行中（未招募）
1 期
To investigate safety and efficacy of AZD9291 when given orally to patients with EGFRm+/T790M+ non small cell lung cancer. Patients will be chosen from those who have already been prescribed an EGRf TKI medicine (such as Iressa or Tarceva)on Small Cell Lung CancerMedDRA version: 17.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000531-17-ESAstraZeneca AB175
进行中（未招募）
1 期
To investigate safety and efficacy of AZD9291 when given orally to patients with EGFRm+/T790M+ non small cell lung cancer. Patients will be chosen from those who have already been prescribed an EGRf TKI medicine (such as Iressa or Tarceva)on Small Cell Lung CancerMedDRA version: 16.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000531-17-ITAstraZeneca AB175
进行中（未招募）
1 期
A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell CarcinomaEUCTR2017-000594-37-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.120